We are a 501(c)3 tax-exempt organization that provides support, education, and hope for a cure to all families with children battling these life-threatening diseases.
What are chILD disorders?
Children’s Interstitial Lung Disease (chILD) is a group of rare pediatric lung diseases. There are more than 30 disorders included under the chILD umbrella. The mission of the chILD Foundation is to fund vital research to fight for the promise of more breaths. Such research offers children and their families hope, better treatments and, ultimately, a cure. chILD disorders are true “orphan” diseases, with less than 10,000 estimated cases in the U.S.. Your support will have a truly profound effect on individual children who struggle for each breath and their families that care for them. Learn MoreA breath is a tiny thing.
It’s easy to miss. And so are these rare lung diseases. The truth is, most of us aren’t aware of chILD because these ailments don’t impact as many children as other afflictions. But that’s why your help can make such a difference in fighting back, and these kids are counting on you with every breath. Watch the VideoYour support helps:
Fund research for treatment & cures
at multiple research centers around the country
Document diseases and patients
to expand the case registry and identify additional disease strains
Educate medical professionals
to enable more effective diagnosis and treatment
Support chILD families
to be their partner in hope and advocacy
chILD Central
News and Inspiration from the chILD Community
Wayne I. Danson assumes role of Chairman of the Foundation’s Board of Directors
The chILD Foundation today announced that effective September 1, 2020, Wayne I. Danson has assumed the role as Chairman of the Foundation’s Board of Directors. He has been an active member of the Board since 2016. In his new role, Wayne will leverage his deep experience in corporate and financial management to further advance the […]
Phase III InPedILD™ trial enrolls first patient to evaluate nintedanib in pediatric population with fibrosing interstitial lung disease
Boehringer Ingelheim announced that the first patient has enrolled in InPedILD™, a global Phase III trial assessing the dosing and safety profile of nintedanib in children and adolescents between 6 and 17 years old with clinically significant fibrosing interstitial lung disease (ILD).
